Dynavax Technologies Corp at JMP Securities Life Sciences Conference Transcript
All right. Well, thank you again for joining us at JMP Securities Life Science Conference. My name is Roy Buchanan. I'm one of the biotech equity analysts researcher. We're happy to have the next company with us, Dynavax Technologies. And here on stage, we have Ryan Spencer, the CEO; and in the audience is Kelly MacDonald, CFO. We have Nicole Spencer and Paul Cox on the Investor Relations team.
So thank you for joining us, Ryan, to give us the download on Dynavax.
Questions & Answers
Pretty exciting year coming up, you guys, exciting financial results pretty much every quarter now, but maybe give us a 30-second intro to what Dynavax is and what you're doing.
Well, first of all, thank you for having us, Roy. We really appreciate it. The short intro is we've been organizing mostly around our adult hepatitis B vaccine, HEPLISAV-B, as you noted, has been making great
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |